Literature DB >> 35669524

Apyretic pulmonary oedema revealing Cardiobacterium hominis endocarditis: Case report and review of literature.

Laurine Milliere1, Caroline Loïez1, Pierre Patoz2, Audrey Charlet1, Claire Duployez1, Frédéric Wallet1.   

Abstract

Cardiobacterium hominis is a member of the HACEK group of bacteria, responsible for infective endocarditis, mainly in patients with damaged or prosthetic valves. The low virulence of this organism can explain the insidious presentation and subacute or chronic progression of C. hominis infective endocarditis. Here, a 41-year-old man with a past history of surgery for a Waldhausen type aortic coarctation was hospitalised with dyspnea and chest pains revealing an acute pulmonary oedema, without fever. Transesophageal echocardiography indicated a 20 mm vegetation on biscuspid aortic valve. Six sets of blood culture were positive with Cardiobacterium hominis. In case of lack of fever, the diagnosis of infectious endocarditis is difficult because other symptoms are non-specific and biological markers of inflammatory syndrome are quiet or non-existent. This is the first case of C. hominis infectious endocarditis with a clinical presentation of acute pulmonary oedema in the literature. We report here an apyretic pulmonary oedema revealing C. hominis endocarditis and a review of the literature on apyretic infective endocarditis due to C. hominis.
© 2022 The Authors.

Entities:  

Keywords:  16S RNA PCR; Apyrexia; Cardiobacterium hominis; Endocarditis; HACEK; MALDI TOF MS

Year:  2022        PMID: 35669524      PMCID: PMC9166381          DOI: 10.1016/j.idcr.2022.e01506

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


The HACEK group of bacteria, Haemophilus-Aggregatibacter-Cardiobacterium-Eikenella-Kingella, are small Gram-negative rods involved in 1.3–1.4% of endocarditis [1], [2]. These microorganisms colonize the oropharynx, are slow growing, and their growth is enhanced by the presence of CO2. First identified as a Pasteurella-like organism, Slotnick and Dougherty described Cardiobacterium hominis in 1964 and gave it its present name [3]. Subsequently, C. hominis was reclassified with Suttonella indologenes in the family Cardiobacteriaceae on the basis of 16 S rRNA analysis [4]. The low virulence of this organism may explain the insidious presentation and subacute or chronic progression of C. hominis infective endocarditis, with a tendency to infect damaged or prosthetic valves [5]. Occasionally, complications may arise such as haemodynamic disturbances. We report here an apyretic pulmonary oedema revealing C. hominis endocarditis and a review of the literature on apyretic C. hominis infective endocarditis.

Case report

A 41-year-old man, with a Waldhausen type aortic coarctation operated in childhood was admitted to our hospital in a context of dyspnea and chest pains revealing an acute pulmonary oedema typical of cardiac decompensation, confirmed by X chest ray. The initial examination showed tachycardia (113/min) with blood pressure asymmetry: 130/60 mmHg in left arm and 180/80 in right arm suggesting an aortic dissection. His body temperature was 37.1 °C, respiratory rate 44 breaths/min and oxygen saturation 96%. He had a stage III dyspnea (NYHA). There were no palpable spleen and no peripheral cutaneous endocarditis symptoms. The angio CT scan performed did not reveal aortic dissection. Considering of his cardiac past, the patient was transferred in the cardiac surgery ward. Transesophageal echocardiography demonstrated a 20 mm vegetation on bicuspid aortic valve, with severe aortic insufficiency. Blood test reveal C-reactive protein level at 35 mg/L (normal range < 5 mg/L). The white blood cell count was 9.1 × 109/L with 81% of polynuclear neutrophil, the hemoglobin concentration was 11.1 g/dL, and the platelet count was 284 × 109/L. Six peripheral blood culture sets were performed and incubated in BacT/Alert Virtuo (bioMérieux, Marcy l′Etoile, France). All blood cultures became positive after 34 h of incubation and confirmed the infective endocarditis diagnosis. Gram stain showed pleiomorphic Gram-negative rods with swollen ends arranged in rosette clusters suggesting Cardiobacterium hominis. The first antimicrobial therapy initiating with oxacillin and amoxicillin was modified by ceftriaxone (4 g/day). After 72 h of incubation at 37 °C in 5–10% CO2 in a humid atmosphere, subcultures on chocolate agar plate yielded pale yellow to white colonies, measuring 1 mm (oxidase positive, catalase negative and indole positive). Identification was performed using MALDI-TOF-mass spectrometry (Brucker Daltonics, Wissembourg) giving a 1.96 score for Cardiobacterium hominis. Antibiotic susceptibility testing was performed using disk diffusion method (BioMérieux, Marcy l′Etoile, France) on Mueller-Hinton agar supplemented with 5% horse blood and 20 mg/L ß-NAD (MHF). The strain was susceptible to amoxicillin, amoxicillin-clavulanic acid, piperacillin, cefotaxime, carbapenems, aminoglycosides and fluoroquinolones. The nitrocefin-based test (Nitrocefin SR112, Oxoid microbiology Products, USA) for beta-lactamase production was negative. The treatment with ceftriaxone (4 g/day) was therefore switched to amoxicillin (8 g/day) for 4 weeks. The evolution of infectious process was favorable and the patient remained apyretic throughout his stay. The aortic insufficiency was treated using a mechanical prosthesis after 4 days of medical antibiotic treatment. The culture of the native valve remained sterile and molecular typing with 16 S rRNA gene sequencing confirming Cardiobacterium hominis identification (accession number LR134365.1) based on a 100% identity, using the NCBI database.

Discussion

Cardiobacterium hominis is a Gram-negative facultative anaerobic, non-motile rod. It can be arranged in pairs, short chains, teardrop firms, rosettes, or clusters. C. hominis tend to retain gentian violet at apical points after Gram staining. It is a commensal species of the human oral cavity and nasopharynx but has also been described in the genital tract of some people. The low virulence of C. hominis explains the opportunistic role of this bacterium recognized as a cause of subacute or chronic infective endocarditis [5]. In 2018, a study including 17 patients with HACEK infective endocarditis was reported. The most frequent clinical characteristic was fever at admission, in 16 patients (94%) [2]. In 2019, in a review of the literature, 73 cases of infective endocarditis caused by C. hominis were described and the mainly clinical feature of these patients was also fever in 54/70 (77%) [6]. In our case, the patient presented an acute pulmonary oedema without fever on admission. Fifteen other cases of C. hominis apyretic endocarditis have been reported in the literature over the last 50 years (Table 1).
Table 1

Review of the literature about Cardiobacterium hominis apyretic infectious endocarditis.

ReferencesAge (y) / SexMedical historySymptoms at admissionCardiac symptoms at admissionInitial laboratory investigationsOutcome
[7]58/MAttacks of chest painMalaise and shortness of breath following an influenza-like illnessSigns of aortic incompetenceCongestive heart failureL: 6,5 × 109/LESR: 25 mm/hAortic valve replacementGood outcome
[8]28/MMurmurs of aortic stenosis and aortic regurgitationFatigueLeg pain of 2 month’s durationSystolic and diastolic murmurTTE: Aortic vegetationsL: 10,3 × 109/LAortic valve replacementGood outcome
[9]28/MNone2 years history of transient vertiginous attacksIntermittent vertical diplopiaTendency to weave towards the left side while walkingSlurring of his speechSystolic murmurCarotid arteriography: an embolus of cerebral arteryBlood count normalGood outcome
[5]63/FRheumatic fever and a heart murmurDyspnea following exertion and atrial fibrillationAortic and mitral stenosis, mitral regurgitationRight hemiparesis: a cerebral hemorrhagic infarctionProgressive symptoms of congestive heart failureSystolic murmurEchocardiogram: mitral stenosis, right ventricular dilation, abnormal septal motion, a dilated left atrium, and abnormal aortic valve closure. No vegetationsAt surgery, aortic vegetationsL: 9,1 × 109/LESR: 96 mm/hAortic and mitral valve replacement and tricuspid valve annuloplastyGood outcome
[10]55/MCongestive heart failure secondary to bicuspid aortic valveCarpentier-Edwards prosthesis aortic valve replacementWeaknessEmesis and melenaAfter Upper Gastrointestinal EndoscopySystolic murmurEchocardiogram: Dilated, hypokinetic left ventricle with hypertrophyAt surgery, prosthetic aortic valve had vegetationsL: 29,9 × 109/LAortic valve replacementGood outcome
[11]40/MEmbolic occlusion of the right popliteal arterySudden pain left calf (= embolic occlusion of the left fibular artery)Diastolic murmurTOE: Bicuspid aortic vegetationsESR: 6 mm/hCRP: 37 mg/LAortic valve replacementGood outcome
[12]17/MCongenital aortic stenosisHomograft aortic valve replacementDental treatmentLethargyNight sweats for 3 weeksDiastolic and systolic murmurEchocardiogram: left ventricular hypertrophyTTE: Non-coronary cusp of the aortic homograft vegetationBlood count normalESR: 4 mm/hCRP undetectableAortic valve replacementGood outcome
[13]66/FDiabetes mellitusDental cariesChest discomfortFatigabilitySystolic and diastolic murmurTOE: Aortic vegetationsL: 8,5 × 109/LAortic valve replacementGood outcome
[14]63/MPorcine aortic valve for severe stenosis across his native bicuspid aortic valveDental caries and tooth erosionsNightly sweatsWeight lossImmune thrombocytopenic purpura refractory to steroidsSplenomegalyHolosystolic murmurTTE: A degenerated aortic valve prosthesis with moderate aortic stenosis and aortic insufficiencyNo vegetationL: 9.3 × 109/LGood outcome
[15]61/MCarpentier-Edwards prosthesis aortic valve replacement3 episodes of Streptococcus sanguinis endocarditisLethargyWeight lossChillsNight sweats for 2 monthsTTE: Minimal calcifications and an aortic insufficiencyTOE: No signs of endocarditisL: 8,2 × 109/LCRP: 17 mg/LGood outcome
[16]60/MDermotological lesion treated with corticoidsAtypical chestConstrictive painDiastolic murmurTOE: Large valvular vegetation right coronary aortic cuspL: 9.1 × 109/LCRP: 24 mg/LValve replacement
[17]12/MTetralogy of FallotReplacements of right ventricle to pulmonary artery complicated by Staphylococcus aureus mediastinitisPoor dentitionFatigueDecreased endurance of 2–3 weeks durationSystolic and diastolic murmurEchocardiogram: Valve with a suggestion of mass attached to the leafletTTE: Mass on a pulmonary valve leaflet concerning for a possible vegetationL: 5.9 × 109/LESR: 25 mm/hCRP: 11.5 mg/LNot stated
[18]47/MDyspnea, orthopnea, exertional chest heaviness and hemoptysis 4 months previouslyDental procedureWorsening malaiseFatigueDrenching night sweatsAnorexiaWeight lossAortic and diastolic murmurTOE: Bicuspid aortic vegetationsMagnetic resonance angiography: Septic cerebral embolusL: 14.1 × 109/LCRP: 64 mg/LESR: 28 mm/hAortic valve replacementResidual left-sided numbness at three-month follow-up
[19]56/MWeaned smokingOverweightPelvic girdle and scapular painAnemiaTTE: Tricuspid valve endocarditisTOE: Tricuspid valve vegetationChest scan: Septic pulmonary embolismCRP: 69 mg/LTricuspid valve replacementGood outcome
[20]60/MValve-sparing aortic root replacement for aortic regurgitationDental procedureEsophagogastroduodenoscopy and colonoscopy 4 weeks beforeFatigue with anemia over a 3-month periodHolosystolic murmurTTE and TOE: Aortic valve vegetationBrain magnetic resonance imaging (MRI): multiple acute lacunar infarctions (= cerebral embolism)L: 8,3 × 109/LCRP: 5.2 mg/LAortic valve replacementGood outcome

L: leukocytes, ESR: erythrocyte sedimentation rate, TTE: transthoracic echocardiography, TOE: transesophageal echocardiography, CRP: C-reactive protein

Review of the literature about Cardiobacterium hominis apyretic infectious endocarditis. L: leukocytes, ESR: erythrocyte sedimentation rate, TTE: transthoracic echocardiography, TOE: transesophageal echocardiography, CRP: C-reactive protein The majority of patients was male 13/15 (87%) with a median age of 56 years. Native-valve endocarditis was more common than prosthetic-valve endocarditis. Aortic valve was the site of infection the most frequently found in 12/15 (80%), the remaining sites being 1 case of tricuspid valve infection, 1 case of pulmonary valve infection and 1 case unknown. As for clinical characteristics at admission, fatigue and malaise were the most frequent in 9/15 (60%), followed by night sweats in 4/15 (27%) and weight loss in 3/15 (20%). Other symptoms found were leg pain, splenomegaly, chest pain and shortness of breath. In terms of laboratory data, in the majority of cases white blood cell count was normal in 11/15 (73%). The C-reactive protein concentration and the erythrocyte sedimentation rate were increased in 6/15 and 4/15 respectively, however the level remains low. The clinical presentation of C. hominis endocarditis is known to be insidious, particularly in the absence of fever: indeed, other symptoms are non-specific and biological markers of inflammatory syndrome are discrete or non-existent. We note here that no case associating acute pulmonary oedema and C. hominis have been reported in the literature. This presentation was probably due to the evolution of the cardiac process complicated by C. hominis endocarditis. In our case, six blood cultures were positive for C. hominis with a relatively short delay of 34 h. As described previously, improvements to conventional blood culture techniques allow the detection of C. hominis with available automated blood culture systems within the standard incubation period of 5–6 days in 95% of the cases if the patient did not received antibiotics [21], [22]. For all studies presented in Table 1, the microbiological diagnosis of Cardiobacterium endocarditis was made by detection of the pathogen in blood cultures, except for one case [11] diagnosed in the embolic material by broad range polymerase chain reaction amplification of 16 S ribosomal RNA. The standard treatment of endocarditis caused by HACEK microorganisms is intravenous ceftriaxone (2 g/day) for 4 weeks in native valve and 6 weeks in prosthetic valve [23], [24]. Due to the emergence of β-lactamase producing strains [25], the detection of production of β-lactamase is required. In absence of the enzyme, the strain is susceptible to ampicillin and the treatment may be de-escalated to a more restrictive-spectrum antibiotic. Endly, ciprofloxacin may be an option for penicillin and cephalosporin intolerance [23], [24]. In the review of the 15 cases, the most common complications were embolic events in 6/15 (40%), including 3 patients with embolic lesions to the central nervous system (CNS) (50%) and 3 patients with peripheral emboli (2 patients with embolic occlusion of the fibular artery and 1 patient with pulmonary embolism). These results are in line with Wormser et al.: embolic events were seen in 44% of patients [5]. Nevertheless, CNS emboli were observed in 21–22% of cases of complications of C. hominis endocarditis [6], [26]. In most cases, the prognosis of patients is favourable [6], however valve replacement is required in the majority of cases. In our review, 11/15 patients (73%) underwent surgery therapy in addition to medical treatment. In conclusion, this case illustrates the importance of suspecting C. hominis infectious endocarditis in patient with a clinical presentation of acute pulmonary oedema. Endocarditis should be suspected even in absence of fever.

Conflicts of interest

The authors declare that they have no conflict of interest.
  26 in total

1.  Emerging data indicating that extended incubation of blood cultures has little clinical value.

Authors:  Melvin P Weinstein
Journal:  Clin Infect Dis       Date:  2005-10-28       Impact factor: 9.079

2.  Cardiobacterium hominis endocarditis.

Authors:  J Midgley; S P LaPage; B A Jenkins; G I Barrow; M E Roberts; A G Buck
Journal:  J Med Microbiol       Date:  1970-02       Impact factor: 2.472

3.  Atypical presentation of Cardiobacterium hominis endocarditis.

Authors:  M J Wong; R M Chan
Journal:  Can Med Assoc J       Date:  1982-09-15       Impact factor: 8.262

Review 4.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

Review 5.  Cardiobacterium hominis endocarditis: Two cases and a review of the literature.

Authors:  A N Malani; D M Aronoff; S F Bradley; C A Kauffman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

6.  Transfer of Kingella indologenes (Snell and Lapage 1976) to the genus Suttonella gen. nov. as Suttonella indologenes comb. nov.; transfer of Bacteroides nodosus (Beveridge 1941) to the genus Dichelobacter gen. nov. as Dichelobacter nodosus comb. nov.; and assignment of the genera Cardiobacterium, Dichelobacter, and Suttonella to Cardiobacteriaceae fam. nov. in the gamma division of Proteobacteria on the basis of 16S rRNA sequence comparisons.

Authors:  F E Dewhirst; B J Paster; S La Fontaine; J I Rood
Journal:  Int J Syst Bacteriol       Date:  1990-10

7.  Infective endocarditis caused by slow-growing, fastidious, Gram-negative bacteria.

Authors:  J J Ellner; M S Rosenthal; P I Lerner; M C McHenry
Journal:  Medicine (Baltimore)       Date:  1979-03       Impact factor: 1.889

8.  Subacute bacterial endocarditis caused by Cardiobacterium hominis: A case report.

Authors:  Davie Wong; Julie Carson; Andrew Johnson
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Jan-Feb       Impact factor: 2.471

9.  Hemolytic Anemia in a Patient with Subacute Bacterial Endocarditis by Cardiobacterium hominis: A Case Report.

Authors:  Motohiro Shingu; Naoto Ishimaru; Jun Ohnishi; Shimpei Mizuki; Yohei Kanzawa; Kei Kawano; Takahiro Nakajima; Nobuya Sano; Saori Kinami
Journal:  Intern Med       Date:  2021-05-22       Impact factor: 1.271

10.  HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort.

Authors:  Stephen T Chambers; David Murdoch; Arthur Morris; David Holland; Paul Pappas; Manel Almela; Nuria Fernández-Hidalgo; Benito Almirante; Emilio Bouza; Davide Forno; Ana del Rio; Margaret M Hannan; John Harkness; Zeina A Kanafani; Tahaniyat Lalani; Selwyn Lang; Nigel Raymond; Kerry Read; Tatiana Vinogradova; Christopher W Woods; Dannah Wray; G Ralph Corey; Vivian H Chu
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.